Sign up to save your podcasts
Or
Share Managing diabetes in the elderly: A primary care perspective
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Managing diabetes in the elderly: A primary care perspective
How can healthcare providers best navigate the unique complexities of diabetes in an aging population?
Our host, Dr. Jeremy Gilbert, explores the multifaceted nature of type 2 diabetes management in the elderly with Dr. Peter Lin, Director of Primary Care Initiatives at the Canadian Heart Research Centre and contributing author to the Diabetes Canada Clinical Practice Guidelines.
In this episode, our experts delve into crucial considerations for managing diabetes in older people, including comorbidities, cognition, frailty, hypoglycemia risk, and the use of basal insulins. Hear our experts share their practical strategies for prioritizing care goals, personalizing treatment approaches, fostering multidisciplinary teamwork, and ensuring patient safety and well-being in this vulnerable population.
Don’t miss the conversation!
The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.
Declaration of conflict of interest:
Dr. Jeremy Gilbert:
- Direct financial relationship, including receipt of honoraria: CPD Network, LMC Canada Inc., CSEM, S&L Solutions, liV Agency, Unik Agency, STA. Membership on advisory boards or speakers’ bureaus: AstraZeneca, Abbott, Amgen, Bayer, Insulet, Tandem, Boehringer Ingelheim, Eli Lilly, GSK, HLS Therapeutics, Novartis, Novo Nordisk, Sanofi.
Dr. Peter Lin:
- Direct financial relationship, including receipt of honoraria: AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Merck, Sanofi, Amgen, MDBriefCase, Canadian Heart Research Centre, CCRN, CHIEF, LMC Diabetes & Endocrinology Group, Diabetes Canada, Novo Nordisk, HLS Therapeutics, Medexus Pharmaceuticals, Pri-Med Canada, liV Agency, MEDUCOM Health, The Rounds, Medscape. Membership on advisory boards or speakers’ bureaus: AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Merck, Sanofi, Amgen, MDBriefCase, Canadian Heart Research Centre, CCRN, CHIEF, LMC Diabetes & Endocrinology Group, Diabetes Canada, Novo Nordisk, HLS Therapeutics, Medexus Pharmaceuticals, Pri-Med Canada, liV Agency, MEDUCOM Health, The Rounds, Medscape.
MAT-CA-2500991
View all episodes
By Diving Into DiabetesHow can healthcare providers best navigate the unique complexities of diabetes in an aging population?
Our host, Dr. Jeremy Gilbert, explores the multifaceted nature of type 2 diabetes management in the elderly with Dr. Peter Lin, Director of Primary Care Initiatives at the Canadian Heart Research Centre and contributing author to the Diabetes Canada Clinical Practice Guidelines.
In this episode, our experts delve into crucial considerations for managing diabetes in older people, including comorbidities, cognition, frailty, hypoglycemia risk, and the use of basal insulins. Hear our experts share their practical strategies for prioritizing care goals, personalizing treatment approaches, fostering multidisciplinary teamwork, and ensuring patient safety and well-being in this vulnerable population.
Don’t miss the conversation!
The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.
Declaration of conflict of interest:
Dr. Jeremy Gilbert:
- Direct financial relationship, including receipt of honoraria: CPD Network, LMC Canada Inc., CSEM, S&L Solutions, liV Agency, Unik Agency, STA. Membership on advisory boards or speakers’ bureaus: AstraZeneca, Abbott, Amgen, Bayer, Insulet, Tandem, Boehringer Ingelheim, Eli Lilly, GSK, HLS Therapeutics, Novartis, Novo Nordisk, Sanofi.
Dr. Peter Lin:
- Direct financial relationship, including receipt of honoraria: AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Merck, Sanofi, Amgen, MDBriefCase, Canadian Heart Research Centre, CCRN, CHIEF, LMC Diabetes & Endocrinology Group, Diabetes Canada, Novo Nordisk, HLS Therapeutics, Medexus Pharmaceuticals, Pri-Med Canada, liV Agency, MEDUCOM Health, The Rounds, Medscape. Membership on advisory boards or speakers’ bureaus: AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Merck, Sanofi, Amgen, MDBriefCase, Canadian Heart Research Centre, CCRN, CHIEF, LMC Diabetes & Endocrinology Group, Diabetes Canada, Novo Nordisk, HLS Therapeutics, Medexus Pharmaceuticals, Pri-Med Canada, liV Agency, MEDUCOM Health, The Rounds, Medscape.
MAT-CA-2500991